<DOC>
	<DOCNO>NCT01909427</DOCNO>
	<brief_summary>The purpose study assess efficacy safety CNTO6785 participant active rheumatoid arthritis ( RA ) despite methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>An Efficacy And Safety Study CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>This randomize ( participant assign treatment chance ) , double-blind ( participant study personnel know treatment give ) , placebo-controlled ( placebo appear identical study drug active ingredient ) , multicenter study . The study consist 3 phase : screening phase , treatment phase , follow-up phase . Approximately 250 participant active RA despite MTX therapy randomly assign receive placebo CNTO 6785 double-blind treatment phase . The maximum period active treatment 28 week . The maximum duration study participation 44 week . Participant safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have diagnosis rheumatoid arthritis ( RA ) ( accord revise 1987 criterion American Rheumatism Association ) RA least 6 month prior date signing informed consent screen Have active RA define study persistent disease activity follow criterion : least 6 swollen 6 tender joint use 66/68 joint count time screen baseline ; serum Creactive protein ( CRP ) ≥ 0.8 mg/dL screen erythrocyte sedimentation rate ( ESR ) ≥ 28 mm first hour screen baseline Have treat tolerate methotrexate ( MTX ) treatment dosages 7.5 25 mg/week , inclusive , minimum 6 month prior screen must stable MTX dose minimum 6 week prior first dose study agent Has inflammatory disease RA , might confound evaluation benefit study agent therapy Has diagnosis fibromyalgia Has recent history ( within 12 month prior screen ) uncontrolled , chronic disease include , limited , pulmonary , psychiatric , metabolic disturbance , cardiovascular , endocrine , neurological , hepatic , gastrointestinal , renal , hematological , urological disease investigator believe clinically significant At screen , result laboratory test must meet protocolspecified criterion Has ever receive approved investigational biologic agent rheumatic indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Active rheumatoid arthritis despite methotrexate therapy</keyword>
	<keyword>CNTO 6785</keyword>
	<keyword>Methotrexate</keyword>
</DOC>